3-(4-[[Benzyl(methyl)amino]methyl]phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy.

@article{Piazzi200334Benzylmethylaminomethylphenyl67di,
  title={3-(4-[[Benzyl(methyl)amino]methyl]phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy.},
  author={Lorna Piazzi and Angela Rampa and Alessandra Bisi and Silvia Gobbi and Federica Belluti and Andrea Cavalli and Manuela Bartolini and Vincenza Andrisano and Piero Valenti and Maurizio Recanatini},
  journal={Journal of medicinal chemistry},
  year={2003},
  volume={46 12},
  pages={2279-82}
}
In recent years, the investigation of acetylcholinesterase (AChE) inhibitors has gained further interest, because the involvement of the peripheral site of the enzyme in the beta-amyloid (Abeta) aggregation process has been disclosed. We present here, for the first time, a direct evidence of the Abeta antiaggregating action of an AChE inhibitor (AP2238) purposely designed to bind at both the catalytic and the peripheral sites of the human enzyme. 

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 37 extracted citations

Similar Papers

Loading similar papers…